{"disease":{"id":"intensity-modulated-radiotherapy","name":"intensity modulated radiotherapy"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06826885","title":"Safety and Efficacy of IMPT or IMRT for Breast Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT05994170","title":"Reducing High Risk Primary Tumor Clinical Target Volumes (CTVp1) in Non-metastatic Nasopharyngeal Carcinoma","phase":"NA","overall_status":"RECRUITING","enrollment_count":454,"lead_sponsor_name":"Zhongshan People's Hospital, Guangdong, China","has_results":false},{"nct_id":"NCT06533267","title":"Endoscopic Surgery vs. Intensity Modulated Radiotherapy for Stage I Nasopharyngeal Carcinoma.","phase":"NA","overall_status":"RECRUITING","enrollment_count":442,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT07481786","title":"Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":220,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT07376603","title":"IMRT Alone for Stage IB Nasopharyngeal Carcinoma Without High-Risk Features","phase":"","overall_status":"RECRUITING","enrollment_count":169,"lead_sponsor_name":"Qiaojuan Guo","has_results":false},{"nct_id":"NCT05114707","title":"Camrelizumab Plus Chemoradiotherapy for Patients With Locoregional Cancer of Nasal Cavity and Paranasal Sinuses","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":57,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT05944809","title":"The Effect of Prophylactic TPO Combined with BMS-IMRT to Esophageal Cancer Patients","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":32,"lead_sponsor_name":"JIANYANG WANG","has_results":false},{"nct_id":"NCT05167994","title":"Preoperative IMRT With Concurrent Anlotinib for Localised Extremity or Trunk Sarcoma （SPARE-01）","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT05235100","title":"Preoperative IMRT With Concurrent Apatinib for Localised Extremity or Trunk Sarcoma （SPARE-02）","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false}],"total":9},"guidelines":[],"source":"Drug Landscape verified database"}